42Stockpicking

COLL

Collegium Pharmaceutical IncKøb· 84.1%· 20. aug. 2026
NASDAQ·Healthcare·USD

Henter pris…

Værdiansættelse (TTM)

P/Ei
11,2
12th %ile · 62p
EV/EBITDAi
12,9
41st %ile · 16p
P/Bi
2,8
34th %ile · 64p
P/Si
0,7
15th %ile · 70p
EV/Salesi
0,5
12th %ile · 70p
Div yieldi

Kursudvikling

Pris

Data-readiness

10 års prishistorik er idealet for høj confidence.

Beregnet 22.8.2026full
Prishistorik
11,3 år
Pris-dage
2840
Årsregnskaber
14
Peers
0/0
Valuation
5/6
Fundamentals
8/8
Datovindue
2015-05-07 til 2026-08-21

Blokkere

  • Raw confidence is below the 0.95 high-confidence guardrail.

Mangler før højere confidence

  • Kør compute-multiples for manglende valuation metrics.

Seneste assessment

COLL vurderet 2026-08-22

Score
56.8%
Ikke high-confidence

Raw confidence is below the 0.95 high-confidence guardrail.

Sell watch placeholder

Stores exit-aware fields without issuing sell scores yet.

7%

Current drawdown: Future exit logic can use drawdown from recent high.

Trend break: Future exit logic can use moving-average trend breaks.

Valuation

Compares price paid with earnings, cash-generation proxies and sales.

100%

P/E: Reasonable P/E gets rewarded; very expensive or distressed multiples do not.

Earnings yield: Earnings yield is the inverse P/E lens.

Technicals

Checks trend, momentum and current damage from recent highs.

5%

6M momentum: Positive medium-term momentum confirms sponsorship.

Trend stack: Strong setup keeps price above MA50 and MA200 with MA50 above MA200.

Data quality

Checks whether the assessment has enough recent price, fundamental and valuation data.

75%

Price history depth: More than one trading year gives the technical pillar enough context.

Latest price freshness: Latest live or EOD price should be recent.

Macro/regime

Treats macro as context, not a standalone trading instruction.

47%

VIX: Normal volatility is supportive; panic or complacency is less clean.

10Y-2Y curve: Positive yield curve lowers recession stress.

Fundamentals

Scores growth, margins, capital efficiency, balance-sheet resilience and composite financial-health KPIs.

78%

Revenue growth 3Y: Sustained top-line growth supports durable compounding.

Gross margin: High gross margin gives room for reinvestment and downturns.

Peer/relative context

Adds relative context when sector peers have comparable data.

83%

Peer count: Peer context is only scored when comparable data exists.

P/E vs peers: Own P/E 11.2 vs peer median 20.6; cheaper than peers if business quality is comparable.

Insider activity

Net 90d (aktier)
-20
Net 90d (værdi)
-681 USD
Købere 90d
0
Cluster
DatoPersonRolleTypeAntalVærdiKilde
8.6.2026SANTINI GINO◆ OPT.8.700143.463 USDsec
18.5.2026Freund John Gordon▼ SALG-20-681 USDsec
15.5.2026Freund John Gordon▼ SALG-4.127-142.547 USDsec
15.5.2026Freund John Gordon◆ OPT.8.700143.463 USDsec
14.5.2026BOHLIN GAREN G· ANDET8.741sec
14.5.2026Freund John Gordon· ANDET8.741sec
14.5.2026Balice-Gordon Rita J.· ANDET8.741sec
14.5.2026Glancy Donovan Michael· ANDET17.482sec
14.5.2026SANTINI GINO· ANDET8.741sec
14.5.2026Lurker Nancy· ANDET8.741sec
14.5.2026Paya Carlos V· ANDET8.741sec
13.5.2026Lurker Nancy▼ SALG-4.500-161.861 USDsec
11.5.2026BOHLIN GAREN G▼ SALG-8.700-323.491 USDsec
11.5.2026BOHLIN GAREN G◆ OPT.8.700143.463 USDsec

Earnings

QuarterDateEPS actualEPS estEPS surpriseRevenue surprise
2026Q230.7.20261,921,77+8.8%+8.8%Beat
2026Q130.4.20261,761,52+15.5%+15.5%Beat
2025Q430.1.20262,042,14-4.7%-4.7%Inline
2025Q330.10.20252,251,86+21.0%+21.0%Beat
2025Q230.7.20251,681,85-9.2%-9.2%Miss